Finepoint Capital LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001608126
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2023 · 28 positions · Total reported value $200.80M · Top-10 concentration 75.9% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 54.5% · 2 new · 3 cut · 1 exited
Active Share (vs S&P 500): 96.1% · vs QQQ: 95.9% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -0.5% · vs SPY -2.6% · Prev Value $2.80B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): +0.7% · vs SPY -1.4% · Latest Value $2.71B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2023 13F filing, Finepoint Capital LP disclosed 28 equity positions with a combined reported value of $200.80M. The filing implies a focused portfolio: its ten largest positions account for 75.9% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2023 were MLTX ($18.89M), FOLD ($18.11M), SRPT ($17.62M). By sector, the heaviest allocations are Health Care 66.2%, Other 33.8%.
Versus the prior quarter, Finepoint Capital LP opened 2 new positions, trimmed 3 and fully exited 1, a turnover rate of 54.5% of positions.
The largest new positions opened in Q3 2023 were MLTX ($18.89M), FOLD ($18.11M), SRPT ($17.62M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2023)
- MLTX MOONLAKE IMMUNOTHERAPEUTICS · $18.89M
- FOLD AMICUS THERAPEUTICS INC · $18.11M
- SRPT SAREPTA THERAPEUTICS INC · $17.62M
- PRTA PROTHENA CORP PLC · $16.85M
- LKFT LAKEFRONT BIOTHERAPEUTICS NV · $15.85M
- ASND ASCENDIS PHARMA A/S · $15.34M
- SWTX SPRINGWORKS THERAPEUTICS INC · $12.88M
- CYTK CYTOKINETICS INC · $12.72M
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest Finepoint Capital LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Finepoint Capital LP is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 9 US equity positions with a combined value of $2.80B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: BOSTON, MA, United States
- SEC registration: 801-79330 (status: Approved), registered 2014-04-17
- Regulatory AUM (Form ADV): $5.01B as of 2026-03-24
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 2 hedge funds
- Website: finepointcapital.com
Portfolio Structure
- 9 positions · $2.80B reported value (Q2 2026)
- Top 10 holdings = 100.0% of reported value
- Largest position: SPY (STATE STR SPDR S&P 500 ETF T) at 45.7%
- Average position size: $310.99M
Sector Tilt
- Information Technology 21.2%
- Consumer Discretionary 16.5%
- Energy 0.0%
- (classified holdings cover 38% of value)
Quarterly Activity
- Q2 2026: 1 new, 2 added, 1 reduced, 1 exited
- 5 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
331.42K | $18.89M | 9.41% | New | |
| 2 |
|
1.49M | $18.11M | 9.02% | New | |
| 3 |
|
145.36K | $17.62M | 8.78% | New | |
| 4 |
|
349.30K | $16.85M | 8.39% | New | |
| 5 |
|
458.66K | $15.85M | 7.89% | New | |
| 6 |
|
163.77K | $15.34M | 7.64% | New | |
| 7 |
|
556.93K | $12.88M | 6.41% | New | |
| 8 |
|
431.69K | $12.72M | 6.33% | New | |
| 9 |
|
563.35K | $12.30M | 6.12% | New | |
| 10 |
|
427.00K | $11.82M | 5.89% | New | |
| 11 |
|
556.55K | $11.60M | 5.78% | New | |
| 12 |
|
504.70K | $9.91M | 4.94% | New | |
| 13 |
|
895.82K | $8.01M | 3.99% | New | |
| 14 |
|
325.36K | $7.45M | 3.71% | New | |
| 15 |
|
870.87K | $7.32M | 3.65% | New | |
| 16 |
|
961.25K | $2.42M | 1.21% | New | |
| 17 |
|
125.00K | $415.62K | 0.21% | New | |
| 18 |
|
504.71K | $333.61K | 0.17% | New | |
| 19 |
|
895.00K | $304.30K | 0.15% | New | |
| 20 |
|
548.00K | $168.78K | 0.08% | New | |
| 21 |
|
655.20K | $144.14K | 0.07% | New | |
| 22 |
|
459.91K | $101.27K | 0.05% | New | |
| 23 |
|
540.00K | $86.40K | 0.04% | New | |
| 24 |
|
439.67K | $49.02K | 0.02% | New | |
| 25 |
|
408.33K | $42.59K | 0.02% | New | |
| 26 |
|
490.00K | $34.59K | 0.02% | New | |
| 27 |
|
490.00K | $17.15K | 0.01% | New | |
| 28 |
|
735.00K | $13.52K | 0.01% | New | |
FAQ
What did Finepoint Capital LP buy in 2023-Q3?
In its 2023-Q3 13F filing, Finepoint Capital LP reported 28 equity positions worth $200.80M in aggregate; its largest disclosed positions were MLTX ($18.89M), FOLD ($18.11M), SRPT ($17.62M).
How large is Finepoint Capital LP's portfolio?
Finepoint Capital LP reported $200.80M of long equity holdings across 28 positions as of 2023-Q3. Top-10 holdings account for 75.9% of reported value.
What is Finepoint Capital LP's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.